 DUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 GLOBE NEWSWIRE -- Nabriva Therapeutics plc NASDAQ: NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today published the first data to demonstrate the anti-inflammatory activity of XENLETA lefamulin. 